# Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

> **NCT07059130** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Rubix LS** · enrollment: 150 (estimated)

## Conditions studied

- Crohn Disease (CD)
- Crohns Disease
- Ulcerative Colitis (UC)

## Interventions

- **BIOLOGICAL:** Mirikizumab

## Key facts

- **NCT ID:** NCT07059130
- **Lead sponsor:** Rubix LS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-02-28
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07059130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07059130, "Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07059130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*